CTXR fundamentals
Citius Pharmaceuticals, Inc. earnings per share and revenue
CTXR earnings per share for the last quarter are -1.27 USD whereas the estimation was -0.38 USD which accounts for -231.30% surprise. Company revenue for the same period amounts to 0.00 USD despite the estimated figure of 0.00 USD. Estimated earnings per share for the next quarter are -0.66 USD, and revenue is expected to reach 2.88 M USD. Also watch annual changes over time to get a bigger picture of CTXR earnings per share and revenue dynamics.
Next report date
≈
Report periodQ3 2025
EPS estimate−0.66USD
Revenue estimate2.88 MUSD
EPS
Forecast
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26
−3.40
−1.70
0.00
1.70
3.40
Reported
Estimate
Currency: USD
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26
Reported
−1.50
−1.75
−1.50
−1.25
−1.50
−1.72
−1.30
−1.27
—
—
—
—
Estimate
−1.50
−0.50
3.25
−1.38
−1.25
−1.53
−1.36
−0.38
−0.61
−0.13
0.37
0.29
Surprise
0.00%
−250.00%
−146.15%
+9.09%
−20.00%
−12.66%
+4.76%
−231.30%
—
—
—
—
Revenue
Forecast
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26
0.00
6.00 M
12.00 M
18.00 M
24.00 M
Reported
Estimate
Currency: USD
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26
Reported
—
0.00
0.00
0.00
0.00
0.00
0.00
0.00
—
—
—
—
Estimate
0.00
0.00
21.30 M
0.00
0.00
0.00
0.00
0.00
2.88 M
7.57 M
16.80 M
17.53 M
Surprise
—
—
−100.00%
—
—
—
—
—
—
—
—
—